Sign In to Follow Application
View All Documents & Correspondence

"Suspension Concentrate Formulation Containing Pyrimethanil"

Abstract: The invention provides an aqueous SC formulation comprising: a) 50 to 80 % w/v pyrimethanil; b) 0.2 to 5 % w/v of a polyoxyethylene-polyoxypropylene block copolymer surfactant; and c) 0.2 to 5 % w/v of a naphthalene formaldehyde condensate surfactant. We have found that formulations according to the invention surprisingly do not solidify when milled during manufacture and also exhibit a low propensity to crystallise when stored for prolonged periods.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
05 March 2001
Publication Number
8/2005
Publication Type
INA
Invention Field
PHARMACEUTICALS
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2015-10-28
Renewal Date

Applicants

AVENTIS CROPSCIENCE GMBH
BRUNINGSTRASSE 50, 65929 FRANKFURT AM MAIN, GERMANY.

Inventors

1. GALIA DIMITROVA
AGREVO UK LTD., CHESTERFORD PARK, SAFFRON WALDEN, ESSEX CB10 1XL U.K.

Specification

SUSPENSION CONCENTRATE FORMULATION CONTAINING PYRIMETHANIL
This invention relates to liquid formulations of pyrimethanil and methods for their preparation. In particular, the invention relates to suspension concentrate (SC) formulations that contain high proportions of solid pyrimethanil.
Commercial SC formulations comprising the fungicide pyrimethanil include Mythos® and Scala®. Typically these formulations contain not more than 40% w/v pyrimethanil. Increasing the amount of pyrimethanil in these formulations above 40% would be advantageous, since it would reduce the cost of transporting a given amount of active ingredient. These savings would be particularly significant where pyrimethanil is transported to remote places where distribution is difficult, such as to tropical zones. However, increasing the concentration of pyrimethanil in these formulation leads to milling problems during manufacture and crystallisation during storage.
It is therefore an object of the invention to devise an SC formulation system containing concentrations of pyrimethanil significantly greater than 40% without experiencing the abovementioned problems.
According to a first aspect, the invention provides an aqueous SC formulation comprising a) 50 to 80% w/v pyrimethanil, preferably 60 to 80% w/v; b) 0.2 to 5% w/v of a polyoxyethylene-polyoxypropylene block copolymer surfactant, preferably 0.3 to 1.5 %; and c) 0.2 to 5% w/v of a napthalene formaldehyde condensate surfactant, preferably 0.3 to 1.5%.
We have found that formulations according to the invention surprisingly do not solidify when milled during manufacture and also exhibit a low propensity to crystallise when stored for prolonged periods.
Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer or group of integers, but not the exclusion of any other integer or group of integers including method steps.
Preferably component b) has a molecular weight of 6000 to 14 000, especially 9000 to 13000. Further, component b) contains 20 to 80% w/w of polyoxyethylene, especially

40 to 80%. In particular, the molecular weight of component b) is nominally 12000 and the amount of polyoxyethylene is nominally 70% w/w.
Preferably component c) is a salt, particularly the sodium salt.
Preferably the formulation also comprises a dispersant, such as a polymethyl methacrylate-polyethylene glycol graft copolymer, preferably having a molecular weight of 20000 to 30000, in amounts of 1 to 10% w/v, preferably 3 to 8%.
A particularly preferred SC formulation comprises a) approximately 60% w/v pyrimethanil, b) approximately 0.5% w/v of an ethenylenoxy-propyleneoxy block copolymer surfactant, c) approximately 1% w/v of sodium naphthalene formaldehyde condensate surfactant, d) approximately 5% w/v polymethyl methacrylate-polyethylene glycol graft copolymer, e) approximately 6% w/v propylene glycol and f) approximately 37.5% w/v water.
Our invention is illustrated, by way of example only, with reference to the following.
Examples
A number of formulations of differing composition were prepared. Table 1 shows the components and their concentrations in w/v. In most cases the components are given as their trade name. Their chemical composition and major function are as follows.
Atlox 4894 is polyoxyethylene alkyl ether (NPE-free); acts as a dispersant and wetter.
Atlox 4913 is polymethyl methacrylate-polyethylene glycol graft copolymer; acts as a
dispersant.
Atlox 5406B is a blend of anionic and nonionic surfactants; acts as a dispersant and
wetter.
Morwet D425 is sodium naphtalene formaldehyde condensate; acts as a dispersant
and viscosity modifier.
Synperonic PE F127 is a polyoxyethylene-polyoxypropylene block copolymer; acts as
a dispersant and wetter.
Lauropal X1003 is an ethoxylated alcohol; acts as a wetter.
Polyfon H is sodium lignosulphonate; acts as a dispersant.
Tegopren 5840 is a copolymer consisting of polymethyl siloxanes and
polyoxyethylene-polyoxypropylene segments; acts as a wetter.

Reax 85A is sodium lignosulphonate; acts as a dispersant.
Surfynol 104-E is tetramethyl decynediol and ethylene glycol; acts mainly as a wetter.
Surfynol 420 is polyoxyethylene (1.3 moles) tetramethyl decynediol; acts as a wetter.
Arylan SBC25 is sodium dodecylbenzene sulphonate; acts as a wetter.
Witconol NS 500 LQ is a nonionic surfactant blend; acts as a dispersant.
Synperonic 91/6 is polyoxyethylene (6 moles) synthetic primary C9/C11 alcohol; acts as
a wetter.
Emcol CC9E is polypropylene glycol (9 moles) diethylmonium chloride; acts as a
dispersant and viscosity modifier.
Aerosol OT/ S is dioctyl sodium sulfosuccinate; acts as a wetter.
Each formulation was prepared as follows.
Method
All components (except aqueous Kelzan pregel) are dispersed using a high speed mixer. The dispersion is passed through a bead mill under such conditions to achieve the desired particle size distribution and viscosity. Aqueous Kelzan pregel is added to the milled suspension.
Formulations 1 and 2 are formulations of the invention. The remaining formulations are by way of comparison. Each formulation was analysed in terms of milling performance and extent of crystallisation after 2 weeks storage at 54 °C. The results are as follows
Milling performance
Formulations 3 to 6, 13 to 18, 20 and 24 solidified during milling.
Formulations 1, 2, 7 to 12, 19, 21, 22 and 23 exhibited no milling problems.
Extent of crystallisation after storage at 54 °C
Formulations 7 to 12, 19, 21, 22 and 23 exhibited crystal growth after 2 weeks at 54°C,
this was particularly marked with 11, 19, 21 and 23.
Formulation 2 showed very slight crystallisation.
Formulation 1 showed no crystal growth.(Table Removed)

Claims
1 An aqueous SC formulation comprising a) 50 to 80% w/v pyrimethanil, b) 0.2 to
5% w/v of a polyoxyethylene-polyoxypropylene block copolymer surfactant, and
c) 0.2 to 5% w/v of a napthalene formaldehyde condensate surfactant.
2 A formulation according to claim 1 wherein component b) has a molecular
weight of 6000 to 14 000.
3 A formulation according to claim 1 wherein component b) has a molecular
weight of 9000 to 13000.
4 A formulation according to claim 1 wherein component b) contains 20 to 80%
w/w of polyoxyethylene.
5 A formulation according to claim 1 wherein component b) contains 40 to 80%
w/w of polyoxyethylene.
6 A formulation according to claim 1 wherein the molecular weight of component
b) is nominally 12000 and the amount of polyoxyethylene is nominally 70% w/w.
7 A formulation according to any preceding claim wherein component c) is a salt.
8 A formulation according to any preceding claim which also comprises a
polymethyl methacrylate-polyethylene glycol graft copolymer dispersant.
9 A formulation according to claim 8 wherein the dispersant has a molecular
weight of 20000 to 30000, in amounts of 1 to 10% w/v.
10 A formulation comprising a) approximately 60% w/v pyrirnethanil, b)
approximately 0.5% w/v of an ethenylenoxy-propyleneoxy block co-polymer
surfactant, c) approximately 1% w/v of sodium naphthalene formaldehyde
condensate surfactant, d) approximately 5% w/v polymethyl methacrylate-
polyethylene glycol graft copolymer, e) approximately 6% w/v propylene glycol
and f) approximately 37.5% w/v water.

Documents

Orders

Section Controller Decision Date

Application Documents

# Name Date
1 in-pct-2001-00185-del-Correspondence-Others-(22-05-2008).pdf 2008-05-22
1 IN-PCT-2001-00185-DEL-RELEVANT DOCUMENTS [23-01-2020(online)].pdf 2020-01-23
2 IN-PCT-2001-00185-DEL-RELEVANT DOCUMENTS [29-01-2019(online)].pdf 2019-01-29
2 in-pct-2001-185-del-pct-409.pdf 2011-08-20
3 in-pct-2001-185-del-pct-210.pdf 2011-08-20
3 269565-IN-PCT-2001-00185-DEL.pdf 2018-12-21
4 in-pct-2001-185-del-pct-101.pdf 2011-08-20
4 IN-PCT-2001-00185-DEL-RELEVANT DOCUMENTS [04-01-2018(online)].pdf 2018-01-04
5 in-pct-2001-185-del-gpa.pdf 2011-08-20
5 Form 27 [07-03-2017(online)].pdf 2017-03-07
6 Other Patent Document [13-09-2016(online)].pdf 2016-09-13
6 in-pct-2001-185-del-form-5.pdf 2011-08-20
7 in-pct-2001-185-del-form-3.pdf 2011-08-20
7 In-pct-2001-00185-del-Claims-(29-09-2015).pdf 2015-09-29
8 in-pct-2001-185-del-form-2.pdf 2011-08-20
8 In-pct-2001-00185-del-Correspondence Others-(29-09-2015).pdf 2015-09-29
9 In-pct-2001-00185-del-Description (Complete)-(29-09-2015).pdf 2015-09-29
9 in-pct-2001-185-del-form-19.pdf 2011-08-20
10 In-pct-2001-00185-del-Form-2-(29-09-2015).pdf 2015-09-29
10 in-pct-2001-185-del-form-1.pdf 2011-08-20
11 In-pct-2001-00185-del-GPA-(29-09-2015).pdf 2015-09-29
11 in-pct-2001-185-del-description (complete).pdf 2011-08-20
12 In-pct-2001-00185-del-Marked Claims-(29-09-2015).pdf 2015-09-29
12 in-pct-2001-185-del-corrspondence-po.pdf 2011-08-20
13 DOA.pdf 2015-07-10
13 in-pct-2001-185-del-corrspondence-others.pdf 2011-08-20
14 Form 6 (IN PCT 2001 00185 DEL).pdf 2015-07-10
14 in-pct-2001-185-del-claims.pdf 2011-08-20
15 In-Pct-2001-00185-del-Assignment-(10-07-2015).pdf 2015-07-10
15 in-pct-2001-185-del-abstract.pdf 2011-08-20
16 In-Pct-2001-00185-del-Correspondence Others-(10-07-2015).pdf 2015-07-10
16 IN-PCT-2001-185-DEL-Form-3-(01-09-2011).pdf 2011-09-01
17 IN-PCT-2001-185-DEL-Correspondence Others-(01-09-2011).pdf 2011-09-01
17 In-Pct-2001-00185-del-Form-1-(10-07-2015).pdf 2015-07-10
18 In-Pct-2001-00185-del-Form-2-(10-07-2015).pdf 2015-07-10
18 in-pct-2001-185-del-Form-3-(07-02-2013).pdf 2013-02-07
19 In-Pct-2001-00185-del-GPA-(10-07-2015).pdf 2015-07-10
19 in-pct-2001-185-del-Correspondence Others-(07-02-2013).pdf 2013-02-07
20 in-pct-2001-185-del-1-Correspondence Others-(07-02-2013).pdf 2013-02-07
20 POA.pdf 2015-07-10
21 Assignment.pdf 2015-06-24
21 In-pct-2001-185-del-Correspondence-Others-(03-09-2013).pdf 2013-09-03
22 In-pct-2001-185-del-Correspondence Others-(13-09-2013).pdf 2013-09-13
22 Petition 137.pdf 2015-06-24
23 In-Pct-2001-00185-del-Assignment-(18-06-2015).pdf 2015-06-18
23 in-pct-2001-00185-del-Petition-137-(28-01-2014).pdf 2014-01-28
24 in-pct-2001-00185-del-Form-3-(28-01-2014).pdf 2014-01-28
24 In-Pct-2001-00185-del-Correspondence Others-(18-06-2015).pdf 2015-06-18
25 In-pct-2001-00185-del-Correspondence Others-(19-02-2015).pdf 2015-02-19
25 in-pct-2001-00185-del-Correspondence-Others-(28-01-2014).pdf 2014-01-28
26 In-pct-2001-00185-del-Form-3-(19-02-2015).pdf 2015-02-19
26 in-pct-2001-185-del-GPA-(25-02-2014).pdf 2014-02-25
27 in-pct-2001-185-del-Correspondence Others-(30-07-2014).pdf 2014-07-30
27 in-pct-2001-185-del-Form-2-(25-02-2014).pdf 2014-02-25
28 in-pct-2001-185-del-Form-1-(25-02-2014).pdf 2014-02-25
28 in-pct-2001-185-del-Form-3-(30-07-2014).pdf 2014-07-30
29 in-pct-2001-185-del-Abstract-(25-02-2014).pdf 2014-02-25
29 in-pct-2001-185-del-Correspondence Others-(25-02-2014).pdf 2014-02-25
30 in-pct-2001-185-del-Claims-(25-02-2014).pdf 2014-02-25
31 in-pct-2001-185-del-Abstract-(25-02-2014).pdf 2014-02-25
31 in-pct-2001-185-del-Correspondence Others-(25-02-2014).pdf 2014-02-25
32 in-pct-2001-185-del-Form-1-(25-02-2014).pdf 2014-02-25
32 in-pct-2001-185-del-Form-3-(30-07-2014).pdf 2014-07-30
33 in-pct-2001-185-del-Correspondence Others-(30-07-2014).pdf 2014-07-30
33 in-pct-2001-185-del-Form-2-(25-02-2014).pdf 2014-02-25
34 In-pct-2001-00185-del-Form-3-(19-02-2015).pdf 2015-02-19
34 in-pct-2001-185-del-GPA-(25-02-2014).pdf 2014-02-25
35 In-pct-2001-00185-del-Correspondence Others-(19-02-2015).pdf 2015-02-19
35 in-pct-2001-00185-del-Correspondence-Others-(28-01-2014).pdf 2014-01-28
36 in-pct-2001-00185-del-Form-3-(28-01-2014).pdf 2014-01-28
36 In-Pct-2001-00185-del-Correspondence Others-(18-06-2015).pdf 2015-06-18
37 in-pct-2001-00185-del-Petition-137-(28-01-2014).pdf 2014-01-28
37 In-Pct-2001-00185-del-Assignment-(18-06-2015).pdf 2015-06-18
38 In-pct-2001-185-del-Correspondence Others-(13-09-2013).pdf 2013-09-13
38 Petition 137.pdf 2015-06-24
39 Assignment.pdf 2015-06-24
39 In-pct-2001-185-del-Correspondence-Others-(03-09-2013).pdf 2013-09-03
40 in-pct-2001-185-del-1-Correspondence Others-(07-02-2013).pdf 2013-02-07
40 POA.pdf 2015-07-10
41 In-Pct-2001-00185-del-GPA-(10-07-2015).pdf 2015-07-10
41 in-pct-2001-185-del-Correspondence Others-(07-02-2013).pdf 2013-02-07
42 In-Pct-2001-00185-del-Form-2-(10-07-2015).pdf 2015-07-10
42 in-pct-2001-185-del-Form-3-(07-02-2013).pdf 2013-02-07
43 In-Pct-2001-00185-del-Form-1-(10-07-2015).pdf 2015-07-10
43 IN-PCT-2001-185-DEL-Correspondence Others-(01-09-2011).pdf 2011-09-01
44 In-Pct-2001-00185-del-Correspondence Others-(10-07-2015).pdf 2015-07-10
44 IN-PCT-2001-185-DEL-Form-3-(01-09-2011).pdf 2011-09-01
45 in-pct-2001-185-del-abstract.pdf 2011-08-20
45 In-Pct-2001-00185-del-Assignment-(10-07-2015).pdf 2015-07-10
46 Form 6 (IN PCT 2001 00185 DEL).pdf 2015-07-10
46 in-pct-2001-185-del-claims.pdf 2011-08-20
47 DOA.pdf 2015-07-10
47 in-pct-2001-185-del-corrspondence-others.pdf 2011-08-20
48 In-pct-2001-00185-del-Marked Claims-(29-09-2015).pdf 2015-09-29
48 in-pct-2001-185-del-corrspondence-po.pdf 2011-08-20
49 In-pct-2001-00185-del-GPA-(29-09-2015).pdf 2015-09-29
49 in-pct-2001-185-del-description (complete).pdf 2011-08-20
50 In-pct-2001-00185-del-Form-2-(29-09-2015).pdf 2015-09-29
50 in-pct-2001-185-del-form-1.pdf 2011-08-20
51 In-pct-2001-00185-del-Description (Complete)-(29-09-2015).pdf 2015-09-29
51 in-pct-2001-185-del-form-19.pdf 2011-08-20
52 In-pct-2001-00185-del-Correspondence Others-(29-09-2015).pdf 2015-09-29
52 in-pct-2001-185-del-form-2.pdf 2011-08-20
53 In-pct-2001-00185-del-Claims-(29-09-2015).pdf 2015-09-29
53 in-pct-2001-185-del-form-3.pdf 2011-08-20
54 Other Patent Document [13-09-2016(online)].pdf 2016-09-13
54 in-pct-2001-185-del-form-5.pdf 2011-08-20
55 in-pct-2001-185-del-gpa.pdf 2011-08-20
55 Form 27 [07-03-2017(online)].pdf 2017-03-07
56 in-pct-2001-185-del-pct-101.pdf 2011-08-20
56 IN-PCT-2001-00185-DEL-RELEVANT DOCUMENTS [04-01-2018(online)].pdf 2018-01-04
57 in-pct-2001-185-del-pct-210.pdf 2011-08-20
57 269565-IN-PCT-2001-00185-DEL.pdf 2018-12-21
58 IN-PCT-2001-00185-DEL-RELEVANT DOCUMENTS [29-01-2019(online)].pdf 2019-01-29
58 in-pct-2001-185-del-pct-409.pdf 2011-08-20
59 in-pct-2001-00185-del-Correspondence-Others-(22-05-2008).pdf 2008-05-22
59 IN-PCT-2001-00185-DEL-RELEVANT DOCUMENTS [23-01-2020(online)].pdf 2020-01-23

ERegister / Renewals

3rd: 22 Jan 2016

From 09/08/2001 - To 09/08/2002

4th: 22 Jan 2016

From 09/08/2002 - To 09/08/2003

5th: 22 Jan 2016

From 09/08/2003 - To 09/08/2004

6th: 22 Jan 2016

From 09/08/2004 - To 09/08/2005

7th: 22 Jan 2016

From 09/08/2005 - To 09/08/2006

8th: 22 Jan 2016

From 09/08/2006 - To 09/08/2007

9th: 22 Jan 2016

From 09/08/2007 - To 09/08/2008

10th: 22 Jan 2016

From 09/08/2008 - To 09/08/2009

11th: 22 Jan 2016

From 09/08/2009 - To 09/08/2010

12th: 22 Jan 2016

From 09/08/2010 - To 09/08/2011

13th: 22 Jan 2016

From 09/08/2011 - To 09/08/2012

14th: 22 Jan 2016

From 09/08/2012 - To 09/08/2013

15th: 22 Jan 2016

From 09/08/2013 - To 09/08/2014

16th: 22 Jan 2016

From 09/08/2014 - To 09/08/2015

17th: 22 Jan 2016

From 09/08/2015 - To 09/08/2016

18th: 22 Jul 2016

From 09/08/2016 - To 09/08/2017

19th: 20 Jul 2017

From 09/08/2017 - To 09/08/2018

20th: 20 Jul 2018

From 09/08/2018 - To 09/08/2019